Zimmer revises its regulatory submission in bid to get approval of Biomet acquisition

Zimmer ($ZMH) revealed that it has submitted a revised package to the European Commission to get approval of its $13 billion purchase of Biomet. The revision makes changes from the package proposed in December based on feedback from the commission. The deadline for the commission's decision is May 26. Zimmer still expects the transaction to close by the end of the current quarter. More

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.